Vortioxetine: An Emerging Multimodal Antidepressants for Depression Management

Samruddhi D. Ramole; Mansi A. Dhankani; Amitkumar R. Dhankani; Sunil P. Pawar

doi:10.52711/2321-5836.2026.00053

Research Journal of Pharmacology and Pharmacodynamics

ISSN

2321-5836 (Online)
0975-4407 (Print)

Submit Article

Vortioxetine: An Emerging Multimodal Antidepressants for Depression Management

Author(s): Samruddhi D. Ramole, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar

Email(s): Email ID Not Available

DOI: 10.52711/2321-5836.2026.00053

Address: Samruddhi D. Ramole, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar
Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
*Corresponding Author

Published In: Volume - 18, Issue - 4, Year - 2026

View HTML

Purchase PDF

ABSTRACT:
ABSTRACT: Vortioxetine is a novel multimodal antidepressant widely used for the management of major depressive disorder (MDD). Unlike conventional antidepressants, Vortioxetine exhibits a unique mechanism of action by modulating various serotonin receptors in addition to inhibiting serotonin reuptake. The drug has demonstrated significant efficacy in improving depressive symptoms, cognitive dysfunction, anxiety-related manifestations, and overall quality of life in patients suffering from depression. Vortioxetine possesses favorable pharmacokinetic characteristics including good oral bioavailability, hepatic metabolism primarily through CYP2D6, and minimal influence on body weight and sexual function compared to other antidepressants. Recent studies have highlighted its potential role in neuroprotection, cognitive enhancement, and management of comorbid psychiatric conditions. The present review comprehensively summarizes the pharmacological profile, mechanism of action, pharmacokinetics, therapeutic applications, adverse effects, drug interactions, dosage regimen, recent advancements, and future prospects associated with Vortioxetine.

Keywords:

Cite this article:
Samruddhi D. Ramole, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar. Vortioxetine: An Emerging Multimodal Antidepressants for Depression Management. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(4):395-9. doi: 10.52711/2321-5836.2026.00053

Cite(Electronic):
Samruddhi D. Ramole, Mansi A. Dhankani, Amitkumar R. Dhankani, Sunil P. Pawar. Vortioxetine: An Emerging Multimodal Antidepressants for Depression Management. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(4):395-9. doi: 10.52711/2321-5836.2026.00053 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-4-9

18. REFERENCES:
1. Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-2-(2,4-dimethylphenylsulfanyl) phenyl piperazine as a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206-21
2. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. PharmacolTher. 2015; 145: 43-57.
3. Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine. Int J Neuropsychopharmacol. 2016; 19(8): 1-13.
4. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10): 1557-67.
5. Mahableshwarkar AR, Jacobsen P, Chen Y. A randomized, double-blind trial of vortioxetine versus placebo in major depressive disorder. J Clin Psychiatry. 2015; 76(5): 583-91.
6. Jain R, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled trial of vortioxetine in major depressive disorder. IntClinPsychopharmacol. 2013; 28(4): 215-22.
7. Thase ME, Mahableshwarkar AR, Dragheim M, et al. The efficacy and tolerability of vortioxetine. J Clin Psychiatry. 2016; 77(2): 167-74.
8. Alvarez E, Perez V, Dragheim M, et al. A double-blind study of vortioxetine in major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589-600.
9. Katona C, Hansen T, Olsen CK. A randomized trial of vortioxetine in elderly patients with major depressive disorder. IntClinPsychopharmacol. 2012; 27(4): 215-23.
10. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile. Int J ClinPract. 2014; 68(1): 60-82.
11. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for treatment of major depressive disorder. Expert Opin Drug Discov. 2019; 14(1): 81-89. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015; 40(8): 2025–2037.
12. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression. CNS Spectr. 2014; 19(2): 121-33.
13. Pae CU, Wang SM, Han C, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Expert Opin Drug MetabToxicol. 2015; 11(11): 1845-58.
14. Stahl SM. Mechanism of action of vortioxetine: a novel multimodal antidepressant. CNS Spectr. 2015; 20(1): 1-8.
15. Kennedy SH, Rizvi SJ. Agomelatine and vortioxetine: novel antidepressants for major depressive disorder. Expert OpinPharmacother. 2014; 15(2): 321-30.
16. Chen G, Lee R, Højer AM, et al. Pharmacokinetic drug interactions involving vortioxetine. Clin Drug Investig. 2013; 33(10): 727-36.
17. Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized trial comparing vortioxetine and agomelatine in adults with major depressive disorder. J Psychopharmacol. 2015; 29(5): 589-600.
18. Fagiolini A, Florea I, Loft H, et al. Effectiveness of vortioxetine in patients with major depressive disorder and anxiety symptoms. CNS Spectr. 2020; 25(5): 661-669.
19. Sanchez C, Zangrossi H. The pharmacology and clinical effects of vortioxetine. CNS Drugs. 2017; 31(9): 691-706.
20. Frampton JE. Vortioxetine: a review in major depressive disorder. Drugs. 2016; 76(17): 1675-82.
21. Bai W, Song H, Hu Y, Zhang X, Wang X, Guo C, Qiu B, Dong Z. Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Drug Des DevelTher. 2023; 17: 3035-3046. doi:10.2147/DDDT.S428771.
22. Fagiolini A, Adair M, Petersen KB, Areberg J, Christensen MC. Clinical Benefits and Bioequivalence of Vortioxetine Oral Drop Solution Versus Oral Tablets. J Psychopharmacol. 2024; 38(2): 156-161. doi:10.1177/02698811231216320.
23. Fagiolini A, Reines EH, Farovik A, Areberg J. Time to Efficacious Steady State Plasma Concentrations with Slow Titration of Vortioxetine Drops Versus Oral Tablets: A Pharmacokinetic Model. Ann Gen Psychiatry. 2025; 24: 56. doi:10.1186/s12991-025-00598-2.
24. Li Y, Wang T, Liu M, Jia Y, Zhou F, Liang M. Development of Long-Acting Intramuscular Vortioxetine Pamoate Suspensions: Formulation Optimization and Pharmacokinetic Evaluation. Eur J Pharm Biopharm. 2026; 222: 115028. doi:10.1016/j.ejpb.2026.115028.
25. Areberg J, Petersen KB, Chen G, Naik H, Bang-Andersen B. Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals. Basic ClinPharmacolToxicol. 2014; 115(6): 552-559. doi:10.1111/bcpt.12278.